Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

998
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
998
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

798
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
798
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

1.3K
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
1.3K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.6K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.6K
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

26
Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term survival in patients discharged alive from hospital following an intensive care unit admission with sepsis or septic shock in Australia and New Zealand: an observational cohort study.

The Lancet regional health. Western Pacific·2026
Same author

Immediate level change estimates can be biased when interrupted time series analyses aggregate over time using segmented linear regression.

Journal of clinical epidemiology·2026
Same author

Developing a Core Outcome Measurement Set for Adult ICU Patients, the CoreMS-ICU-A Protocol.

Acta anaesthesiologica Scandinavica·2026
Same author

Conservative Oxygen for Unresponsive Patients after Cardiac Arrest.

The New England journal of medicine·2026
Same author

Evaluating Environmental Ward Performance: Insights From Acoustic, Lighting, and Temperature Monitoring in a Palliative Care Unit.

HERD·2026
Same author

CRT-Estimands Framework: consensus based extension of the ICH E9(R1) addendum for cluster randomised trials.

BMJ (Clinical research ed.)·2026

Related Experiment Video

Updated: Apr 25, 2026

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.0K

A multicentre feasibility study evaluating stress ulcer prophylaxis using hospital-based registry data.

Edward Litton1, Glenn M Eastwood2, Rinaldo Bellomo2

  • 1Department of Intensive Care, Royal Perth Hospital, Perth, WA, Australia. paul.young@ccdhb.org.nz.

Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine
|August 28, 2014
PubMed
Summary

This study found it is feasible to collect data for trials comparing proton pump inhibitors (PPIs) and histamine-2 receptor blockers (H2RBs) for stress ulcer prophylaxis (SUP) in ICUs. Existing databases can support future comparative effectiveness research.

More Related Videos

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
10:38

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies

Published on: January 16, 2019

22.0K

Related Experiment Videos

Last Updated: Apr 25, 2026

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.0K
Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
10:38

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies

Published on: January 16, 2019

22.0K

Area of Science:

  • Critical Care Medicine
  • Pharmacology
  • Clinical Trial Feasibility

Background:

  • The optimal agent for stress ulcer prophylaxis (SUP) in intensive care unit (ICU) patients, between histamine-2 receptor blockers (H2RBs) and proton pump inhibitors (PPIs), remains unclear.
  • There is a need for adequately powered comparative effectiveness trials to guide clinical practice.

Purpose of the Study:

  • To assess the feasibility of gathering process-of-care and outcome data from existing databases.
  • To inform the design of a proposed interventional trial for SUP in ICU settings.

Main Methods:

  • A retrospective cohort study was conducted across seven tertiary ICUs in Australia and New Zealand.
  • Data were collected from adult patients admitted between January 1, 2011, and December 31, 2012.
  • Key data points included dispensed doses of PPIs and H2RBs, upper gastrointestinal bleeding, respiratory tract colonization, Clostridium difficile infections, and in-hospital mortality.

Main Results:

  • All participating sites successfully contributed data, indicating ease of access.
  • Median dispensed doses were 477g for PPIs and 408.5g for H2RBs per ICU over two years.
  • The incidence of upper GI bleeding was 1.4%, respiratory colonization was 7.1%, C. difficile infections were 1.4%, and in-hospital mortality was 10.6%.

Conclusions:

  • Existing data sources are adequate for collecting essential process-of-care and outcome measures.
  • This feasibility study supports the development of a registry-based interventional trial for SUP.